

11 May 2026

Temporary shortage of Zyprexa Relprevv olanzapine 405 mg powder for injection

Dear Healthcare Professional,

We wish to advise that there is currently a temporary shortage of Zyprexa Relprevv 405 mg. However, supply of Zyprexa Relprevv 210 mg remains available.

For patients who are clinically stable on Zyprexa Relprevv 405 mg and are affected by this stock shortage, the 405 mg dose may be administered using **two** Zyprexa Relprevv 210 mg vials. Please find information about this described below.

1. Reconstitution

Refer to the reconstitution table below (also included in the Information for Use, IFU) to determine the correct volume of sterile diluent to add to each vial.

- For **each** 210 mg vial, add 1.3 mL of sterile diluent.
- Each vial must be reconstituted separately, according to the instructions for reconstitution.
- Mix each vial vigorously until the suspension appears smooth and uniform in colour and texture.

Note: Each vial contains more diluent than is required for reconstitution. Only the appropriate volume specified in the table below should be added.

STEP 2: Determining sterile diluent volume for reconstitution

Refer to the table at below to determine the amount of sterile diluent to be added to olanzapine pamoate powder for reconstitution. It is important to note that there is more sterile diluent in the vial than needed to reconstitute.

Dose	Vial Strength	Solution to Add
150 mg	210 mg	1.3 mL
210 mg	210 mg	1.3 mL
300 mg	300 mg	1.8 mL
405 mg	405 mg	2.3 mL

2. Administration – total final volume for a 405 mg dose

After reconstituting two 210 mg vials, the total final volume to inject for a 405 mg dose is 2.7 mL, as shown in the administration table below.

ADMINISTRATION

STEP 4: Injecting ZYPREXA RELPREVV

Refer to the table below to determine the final volume to inject.
Suspension concentration is 150mg/ml olanzapine pamoate.

Dose	Final Volume to Inject
150 mg	1 mL
210 mg	1.4 mL
300 mg	2 mL
405 mg	2.7 mL

To achieve a total volume of 2.7 mL, you may wish to do the following:

- Draw up 1.4 mL from one reconstituted 210 mg vial, and
- Draw up 1.3 mL from the second reconstituted 210 mg vial.

This provides the correct total dose of 405 mg (suspension concentration: 150 mg/mL olanzapine pamoate). Any additional solution should be discarded appropriately.

Important reminder

Please take care to distinguish between:

- the volume of diluent added during reconstitution, and
- the final volume to be injected.

These volumes are **not the same** and will vary depending on vial strength and intended dose. Always refer to the appropriate tables in the IFU.

A copy of the IFU is included with every pack of Zyprexa Relprevv.

Please refer to the full [Zyprexa Relprevv datasheet](#), on the Medsafe website for more information on dosage, contraindications, precautions and adverse effects.

If you have any medical enquiries or wish to report any suspected adverse drug reactions, please contact Pharmaco at 0800 80 4079. Alternatively, suspected adverse events may be reported to the Centre for Adverse Reactions Monitoring (CARM) online at <https://pophealth.my.site.com/carmreportnz/s/>

Yours sincerely

Shirley Shen
PHARMACO (NZ) Ltd